Downloads
There has been much discussion about the need for Australia to increase “sovereign capability” in domestic pharmaceutical manufacturing.
Against an international backdrop this article discusses the identified supply chain risks and considers whether such an initiative is commercially feasible in the absence of significant government investment and intervention. It also looks at two key initiatives already in place designed to help mitigate the risk of medicine supply chain shortages.